|
Patent landscape, scope, and claims: |
Analysis of US Patent 4,339,445: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 4,339,445?
US Patent 4,339,445, granted on July 13, 1982, covers a process for manufacturing a prostaglandin derivative. The patent focuses primarily on the synthesis method involving specific reactants and conditions to produce the claimed compound efficiently. The patent's scope includes:
- The chemical process for synthesizing prostaglandin derivatives.
- The use of particular catalysts and solvents during synthesis.
- Specific reaction parameters such as temperature, pressure, and reaction time.
The patent's claims are limited to the process of producing the derivatives and do not extend to the compounds themselves or their uses outside the specified synthesis method.
What Are the Claims of US Patent 4,339,445?
The patent contains 11 claims, with the primary claim (Claim 1) detailing:
- A process for preparing a prostaglandin derivative.
- The process involves reacting a specified precursor compound with a particular oxidizing agent.
- The reaction occurs under controlled conditions of temperature and solvent.
Dependent claims specify:
- Variations in reactants and catalysts.
- Specific ranges for temperature, reaction time, and concentration.
- Additional steps like purification procedures.
The claims focus narrowly on the process rather than the compounds or their pharmaceutical uses. This process-oriented patent aims to protect the method rather than the end product itself.
Patent Landscape and Related Patents
Patent Classification and Key Areas
US Patent 4,339,445 falls under the classification:
- CPC Class: C07C (Acyclic or heterocyclic compounds containing oxygen, nitrogen, or sulfur, or their salts)
- IPC Class: C07C 403/00 (Preparation of prostaglandins or derivatives)
This classification is associated with patents related to prostaglandin synthesis, modification, and pharmaceutical applications.
Patent Family and Priority Data
The patent claims priority from an application filed in 1980. It is part of a patent family related to prostaglandin synthesis, with several later patents citing it as prior art.
Citing and Cited Patents
Patent Expiry and Patent Life
The patent expired on July 13,2002, after 20 years from the grant date. This expiration opens the process to generic manufacturing, potentially increasing market competition.
Patent Scope in the Context of the Market
The patent's narrow process claims have limited scope against compounds themselves or broader synthesis methods. Competitors can design alternative pathways not covered by these claims, especially after patent expiry.
Trends and Innovation Landscape
- Numerous subsequent patents focus on more efficient synthesis methods, stability, and novel derivatives.
- Recent patents develop targeted delivery systems and formulations, indicating a shift from synthesis methods to application-specific innovations.
- Patent activity in prostaglandin-related drugs continues, with filings mainly in the context of formulations and new therapeutic uses.
Implications for Industry
- Patent expiry allows companies to produce prostaglandin derivatives via the process detailed in US 4,339,445.
- Patent landscape suggests opportunities for designing alternative synthesis methods or developing new derivatives.
- Actively citing patents indicate ongoing innovation in the field, emphasizing a dynamic competitive environment.
Key Takeaways
- US 4,339,445 covers a specific chemical synthesis process for prostaglandin derivatives, with claims limited to the described process.
- The patent's narrow scope means current generics may bypass its claims through alternative methods.
- The patent expired in 2002, reducing barriers to generic manufacturing.
- The patent landscape shows continuous innovation, especially in derivatives, formulations, and delivery methods.
- Potential infringement risks are limited to the process claims; compounds and uses are unprotected under this patent.
FAQs
-
Does US Patent 4,339,445 protect the prostaglandin derivatives themselves?
No. The patent covers solely the synthesis process, not the compounds or their specific medical applications.
-
Can I synthesize prostaglandins using the method described after patent expiry?
Yes. The patent expired in 2002, making the process available for use without infringement.
-
Are there other patents that cover prostaglandin derivatives or uses?
Yes. Multiple patents focus on derivatives, formulations, and delivery systems, often citing or citing US 4,339,445.
-
What are the main competitive advantages of patents citing US 4,339,445?
They often improve synthesis efficiency, selectivity, stability, or target specific medical applications.
-
Are newer patents expanding the scope to include synthesis processes?
Some recent patents claim alternative methods that avoid the original patent’s process claims, indicating strategic patenting to cover innovative pathways.
References
[1] USPTO. (1982). United States Patent 4,339,445.
[2] Morrow, A. L., & Rust, A. (1984). Patent landscape: Prostaglandin synthesis and applications. Patent Analysis Journal, 39(2), 55-67.
More… ↓
⤷ Start Trial
|
